Efficacy and Safety Study Comparing Concentration-Controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients.

Trial Profile

Efficacy and Safety Study Comparing Concentration-Controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2017

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Sep 2015 Results from 12 and 24-Month multivariate analysis presented at the 17th Congress of the European Society for Organ Transplantation.
    • 16 Sep 2015 Results of post-hoc analysis presented at the 17th Congress of the European Society for Organ Transplantation
    • 11 Sep 2013 Results comparing tolerability of 2 trials (A2309 and H2304 in in kidney and liver transplant recipients, respectively) presented at the 16th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top